RxDoctor Payments DataLook up a doctor →

Holly Kanavy, DO

Dermatology · Bronx, NYNPI 1386965408

Payments from drug & device makers

$1,220,255in general payments, 2019–2025

Across 782 payments — averaging $1560.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$424K
  • Takeda Pharmaceuticals U.S.A., Inc.$190K
  • E.r. Squibb & Sons, L.L.C.$185K
  • Eli Lilly$104K
  • Amgen$79K
  • Incyte Corporation$63K
  • plus $175K from 21 others

What the payments were for

  • Consulting fees$26,14360%
  • Speaking & faculty fees$6,80516%
  • Travel & lodging$8372%
  • Food & beverage$8,80720%
  • Education$7152%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,220,255 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York

Medicare billing

Part B allowed, 2024
$40,049
Medicare patients
195
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab85$403,214
Skyrizi PenRisankizumab-Rzaa16$311,851
OpzeluraRuxolitinib Phosphate69$147,776
Humira(Cf) PenAdalimumab12$77,753
Dupixent SyringeDupilumab14$48,885
Tacrolimus66$16,074
Ketoconazole332$12,165
Clobetasol Propionate115$8,081
Ammonium Lactate266$5,772
Clindamycin Phosphate98$3,642
Calcipotriene12$3,623
Tretinoin45$3,431
CiclopiroxCiclopirox Olamine56$3,403
Fluocinonide43$2,301
Halobetasol Propionate36$2,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$63,358$147,77669 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.

Other dermatology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →